BMRN:NASDAQ
Biomarin Pharmaceutical Inc
$55.95
arrow_downward
-1.20%(-0.68) 1D
$55.95
0.00% (0.00)
bedtimeAfter hours
Closed: Oct 23, 4:00:01 PM GMT-4 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BMRN...
Open
$56.68
High
$56.81
Low
$55.24
Mkt. cap
10.83B
Avg. vol.
2.33M
Volume
1.68M
P/E ratio
150.84
52-wk high
$70.98
52-wk low
$49.26
EPS
$0.37
Beta
0.22
Shares outstanding
193.57M
No. of employees
3K
Open
$56.68
High
$56.81
Low
$55.24
Mkt. cap
10.83B
Avg. vol.
2.33M
Volume
1.68M
P/E ratio
150.84
52-wk high
$70.98
52-wk low
$49.26
EPS
$0.37
Beta
0.22
Shares outstanding
193.57M
No. of employees
3K
News stories
From web sources and news partners
Yahoo Finance
·
27 minutes ago
Up 35%, How Long Can Coca-Cola Continue Crushing the S&P 500?
Traders Union
·
1 hour ago
Dow gains almost 4% following Gold window closing, Spina notes
Benzinga
·
7 minutes ago
S&P 500, VOO, and SPY Outlook: What Investors Need to Watch This Week
Cassandra Unchained | Michael Burry
·
18 hours ago
Foundations: The Fate of the S&P 500’s Worst Stocks, the Y2K Analogue, and Time for Small Caps?
Profile
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies. BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria.
Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials. Wikipedia
About Biomarin Pharmaceutical Inc
CEOAlexander Hardy
Employees3.22K
FoundedMar 1997
HeadquartersSan Rafael, California, United States
SectorBiotechnology
Websitebiomarin.com
Analyst ratings
Based on 23 analysts giving stock ratings to BMRN in the past 3 months
Strong buy
Buy
18
Hold
5
Sell
0
12-month forecast
Based on 23 Wall Street analysts offering 12 month price targets for BMRN in the last 3 months.
Highest
Current $55.95
$122.00 (+118.05%)
Average
$93.00 (+66.22%)
Lowest
$60.00 (+7.24%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Phil Nadeau TD Cowen | Buy | Maintained | $120.00 | +114.5% | 10/21/2026 |
Sean Laaman Morgan Stanley | Buy | Reiterated | $122.00 | +118.1% | 10/21/2026 |
Allison Bratzel Piper Sandler | Buy | Maintained | $90.00 | +60.9% | 10/21/2026 |
Olivia Brayer Cantor Fitzgerald | Buy | Maintained | $86.00 | +53.7% | 10/19/2026 |
Jessica Fye J.P. Morgan | Buy | Reiterated | $87.00 | +55.5% | 10/20/2026 |
Mohit Bansal Wells Fargo | Buy | Reiterated | $80.00 | +43% | 10/20/2026 |
Unknown Analyst Cantor Fitzgerald | Buy | Maintained | $86.00 | +53.7% | 10/19/2026 |
Whitney Ijem Canaccord Genuity | Buy | Maintained | $114.00 | +103.8% | 10/16/2026 |
Unknown Analyst UBS | Buy | Initiated | $88.00 | +57.3% | 10/14/2026 |
Joon Lee UBS | Buy | Reiterated | $88.00 | +57.3% | 10/15/2026 |
Eliana Merle Barclays | Buy | Maintained | $114.00 | +103.8% | 10/13/2026 |
Jason Gerberry Bank of America Securities | Buy | Maintained | $86.00 | +53.7% | 10/09/2026 |
Luca Issi RBC Capital | Hold | Maintained | $62.00 | +10.8% | 10/08/2026 |
David Lebowitz BMO Capital | Buy | Maintained | $97.00 | +73.4% | 10/06/2026 |
Debjit Chattopadhyay Guggenheim | Buy | Maintained | $86.00 | +53.7% | 09/17/2026 |
Unknown Analyst BMO Capital | Buy | Maintained | $97.00 | +73.4% | 09/15/2026 |
Eric Joseph Citi | Buy | Reiterated | - | - | 09/14/2026 |
Mitchell Kapoor H.C. Wainwright | Hold | Reiterated | $60.00 | +7.2% | 09/10/2026 |
Salveen Richter Goldman Sachs | Hold | Maintained | $70.00 | +25.1% | 08/31/2026 |
Akash Tewari Jefferies | Buy | Maintained | $105.00 | +87.7% | 08/31/2026 |
Sami Corwin William Blair | Hold | Maintained | - | - | 08/31/2026 |
Paul Matteis Stifel Nicolaus | Hold | Maintained | $70.00 | +25.1% | 08/31/2026 |
Yun Zhong Wedbush | Buy | Maintained | $94.00 | +68% | 08/18/2026 |
Christopher Raymond Raymond James | Buy | Maintained | $105.00 | +87.7% | 08/07/2026 |
Cory Kasimov Evercore ISI | Buy | Maintained | $120.00 | +114.5% | 08/07/2026 |
Leland Gershell Oppenheimer | Buy | Reiterated | $97.00 | +73.4% | 08/07/2026 |
Jason Zemansky Bank of America Securities | Buy | Reiterated | $86.00 | +53.7% | 08/06/2026 |
Unknown Analyst Guggenheim | Buy | Maintained | $86.00 | +53.7% | 06/03/2026 |
Unknown Analyst J.P. Morgan | Buy | Maintained | $80.00 | +43% | 05/20/2026 |
Unknown Analyst Citi | Buy | Initiated | - | - | 05/19/2026 |
Joseph Schwartz Leerink Partners | Hold | Reiterated | $62.00 | +10.8% | 05/18/2026 |
William Pickering Bernstein | Buy | Reiterated | $82.00 | +46.6% | 05/05/2026 |
Next call in 8 days
Mon, Nov 2, 3:30 PM
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
- / -$0.11
Revenue / Est. (USD)
- / 1.02B
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 776.13M | 874.56M | 766.21M | 989.71M |
Cost of goods sold | 549.56M | 348.91M | 373.80M | 398.05M |
Cost of revenue | 549.56M | 348.91M | 373.80M | 398.05M |
Research and development expenses | - | - | - | - |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 268.42M | 324.16M | 249.98M | 308.73M |
Operating expense | 273.26M | 329.01M | 254.46M | 382.22M |
Total operating expenses | 822.82M | 677.92M | 628.26M | 780.27M |
Operating income | -46.69M | 196.64M | 137.95M | 209.44M |
Other non operating income | 5.09M | 1.02M | 3.96M | 3.28M |
EBT including unusual items | -26.32M | -27.15M | 141.20M | 61.38M |
EBT excluding unusual items | -26.32M | 214.10M | 149.52M | 159.91M |
Income tax expense | 4.42M | 19.42M | 35.68M | 16.62M |
Effective tax rate | -16.79% | -71.52% | 25.27% | 27.08% |
Other operating expenses | - | - | - | - |
Net income | -30.74M | -46.57M | 105.53M | 44.76M |
Net profit margin | -3.96% | -5.33% | 13.77% | 4.52% |
Earnings per share | 0.12 | 0.46 | 0.76 | 1.20 |
Interest and investment income | 17.85M | 19.21M | 22.56M | 10.48M |
Interest expense | -2.58M | -2.78M | -14.96M | -63.30M |
Net interest expenses | 15.28M | 16.43M | 7.60M | -52.82M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | -28.20M | 209.68M | 154.36M | 307.08M |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events